Biotech firm Cocrystal Pharma is dedicated to researching and creating antiviral therapeutics for serious and chronic viral illnesses. With a focus on hepatitis C virus (HCV), influenza, coronavirus, and norovirus infections, Cocrystal Pharma utilizes structure-based technologies to develop antiviral medications. The firm is undergoing clinical trials for its HCV non-nucleoside polymerase inhibitor, CC-31244, after completing Phase II, and is working on preclinical development trials for its PB2 inhibitor, CC-42344, for influenza infection. Additionally, Cocrystal Pharma is actively identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. The company has collaborations and agreements with Merck Sharp & Dohme Corp, Kansas State University Research Foundation, HitGen, and InterX Inc to develop treatments for various infections. Cocrystal Pharma is headquartered in Bothell, Washington.
Cocrystal Pharma, Inc.'s ticker is COCP
The company's shares trade on the NASDAQ stock exchange
They are based in Tucker, Georgia
There are 11-50 employees working at Cocrystal Pharma, Inc.
It is https://www.cocrystalpharma.com/
Cocrystal Pharma, Inc. is in the Healthcare sector
Cocrystal Pharma, Inc. is in the Biotechnology industry
The following five companies are Cocrystal Pharma, Inc.'s industry peers: